Epilepsy – UCB EP0162

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.

Inclusion Criteria:

  • Participant must be ≥12 years of age at the Baseline/Randomization Visit
  • Participant must have a study caregiver ≥18 years of age at the Screening Visit
  • Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures
  • Other criteria may apply

Complete the form to get connected with new research studies and our team will reach out soon to help determine your eligibility.

View Study on ClinicalTrials.gov

Trial Interest Form

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form